xamoterol has been researched along with benazepril in 1 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (benazepril) | Trials (benazepril) | Recent Studies (post-2010) (benazepril) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 609 | 230 | 142 |
| Protein | Taxonomy | xamoterol (IC50) | benazepril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.0017 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.1047 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.0017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasenfuss, G; Holubarsch, C; Just, H; Thierfelder, L | 1 |
1 other study(ies) available for xamoterol and benazepril
| Article | Year |
|---|---|
Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure.
Topics: Benzazepines; Cardiotonic Agents; Energy Metabolism; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Myocardium; Nitroprusside; Oxygen Consumption; Propanolamines; Vasodilator Agents; Xamoterol | 1991 |